Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer
Status
Conditions
Study type
Funder types
Identifiers
Details and patient eligibility
About
RATIONALE: Learning about quality of life in patients with cancer undergoing embolization may help doctors learn about the side effects of treatment and plan the best treatment.
PURPOSE: This clinical trial is studying quality of life in patients undergoing embolization using yttrium Y 90 glass microspheres for primary or metastatic liver cancer.
Full description
OBJECTIVES:
Primary
- Assess the quality of life (QOL) as defined by the presence or absence of physical, social, emotional, and functional distress in patients with primary or metastatic liver cancer undergoing treatment with radioembolization or transcatheter arterial embolization.
- Compare the time course of QOL measures between treatment groups in patients treated with these regimens.
- Compare the time course of QOL measures between patient subgroups defined by pre-treatment quality of life or tumor burden.
OUTLINE: Patients complete FACT-Hep version 4 surveys on quality of life prior to initiation of embolization, and at 2 weeks and 1 month after completion of embolization.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
DISEASE CHARACTERISTICS:
- Diagnosis of primary hepatocellular cancer or metastatic liver cancer
- Planning radioembolization or transcatheter arterial embolization using yttrium Y 90 glass microspheres
- No encephalopathy
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Bilirubin ≤ 3 mg/dL
- Able to comply with study procedures
PRIOR CONCURRENT THERAPY:
- No prior treatment with radioembolization or transcatheter arterial embolization
Trial design
74 participants in 3 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal